

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/21/2016

Visit the AIDS*info* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at http://aidsinfo.nih.gov/e-news.

Appendix C: Supplemental Information (Last updated February 12, 2014; last reviewed February 12, 2014)

Table A. Likelihood of Developing AIDS or Death Within 12 Months, by Age and CD4 T-Cell Percentage or Log_{10} HIV-1 RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

CD4 Percentage					Log ₁₀ HIV RNA Copy Number				
Age	10%	20%	25%	30%	6.0	5.0	4.0		
Percent Mortality (95% Confidence Interval)									
6 Months	28.7	12.4	8.5	6.4	9.7	4.1	2.7		
1 Year	19.5	6.8	4.5	3.3	8.8	3.1	1.7		
2 Years	11.7	3.1	2.0	1.5	8.2	2.5	1.1		
5 Years	4.9	0.9	0.6	0.5	7.8	2.1	0.7		
10 Years	2.1	0.3	0.2	0.2	7.7	2.0	0.6		
Percent Developing AIDS (95% Confidence Interval)									
6 Months	51.4	31.2	24.9	20.5	23.7	13.6	10.9		
1 Year	40.5	20.9	15.9	12.8	20.9	10.5	7.8		
2 Years	28.6	12.0	8.8	7.2	18.8	8.1	5.3		
5 Years	14.7	4.7	3.7	3.1	17.0	6.0	3.2		
10 Years	7.4	2.2	1.9	1.8	16.2	5.1	2.2		

Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study Group. Lancet. 2003;362:1605-1611.

Table B. Death and AIDS/Death Rate per 100 Person-Years by Current Absolute CD4 Cell Count and Age in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy (HIV Paediatric Prognostic Markers Collaborative Study) and Adult Seroconverters (CASCADE Study)

0		• /		`	• /				
	Absolute CD4 Cell Count (cells/mm³)								
Age (Years)	<50	50-99	100–199	200–349	350-499	500+			
Rate of Death Per 100 Patient-Years									
0–4	59.3	39.6	25.4	11.1	10.0	3.5			
5–14	28.9	11.8	4.3	0.89	0.00	0.00			
15–24	34.7	6.1	1.1	0.71	0.58	0.65			
25–34	47.7	10.8	3.7	1.1	0.38	0.22			
35–44	58.8	15.6	4.5	0.92	0.74	0.85			
45–54	66.0	18.8	7.7	1.8	1.3	0.86			
55+	91.3	21.4	17.6	3.8	2.5	0.91			
Rate of AIDS or Death per 100 Patient-Years									
0–4	82.4	83.2	57.3	21.4	20.7	14.5			
5–14	64.3	19.6	16.0	6.1	4.4	3.5			
15–24	61.7	30.2	5.9	2.6	1.8	1.2			
25-34	93.2	57.6	19.3	6.1	2.3	1.1			
35–44	88.1	58.7	25.5	6.6	4.0	1.9			
45–54	129.1	56.2	24.7	7.7	3.1	2.7			
55+	157.9	42.5	30.0	10.0	5.1	1.8			

Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. *J Infect Dis.* 2008:197:398-404.

Table C. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number and CD4 T-Cell Percentage with Long-Term Risk of Death in HIV-Infected Children^a

Baseline HIV RNA ^c (Copies/mL)		Deaths ^b		
Baseline CD4 Percentage	No. Patients ^d	Number	Percentage	
≤100,000				
≥15%	103	15	(15%)	
<15%	24	15	(63%)	
>100,000				
≥15%	89	32	(36%)	
<15%	36	29	(81%)	

^a Data from the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. *J Infect Dis.* 1997;175(5):1029–1038.

Figure A. Estimated Probability of AIDS Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from Lancet 2003;362:1605-1611

^b Mean follow-up: 5.1 years.

^c Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

d Mean age: 3.4 years.

Figure B. Estimated Probability of Death Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from *Lancet* 2003;362:1605-1611

Figure C. Death Rate per 100 Person-Years in HIV-Infected Children Aged 5 Years or Older in the HIV Paediatric Prognostic Marker Collaborative Study and HIV-Infected Seroconverting Adults from the CASCADE Study*




Figure modified from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. *J Infect Dis.* 2008:197:398-404.

Figure D. Estimated Probability of AIDS Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from *Lancet* 2003;362:1605-1611

Figure E. Estimated Probability of Death Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from Lancet 2003;362:1605-1611